Apitope Announces Completion of Enrolment in Phase IIA Clinical Trial Multiple Sclerosis drug
ATX-MS-1467 is a potential novel treatment developed with the aim of working with the immune system to treat the underlying cause of the disease by restoring immunological balance, instead of only treating the symptoms or suppressing the entire immune system.
Examination of the Phase I MRI results demonstrated a significant decrease of 78% in the number of contrast-enhancing brain lesions in patients with relapsing MSwith ATX-MS-1467.
Merck Serono will complete all development activities from the beginning of Phase II clinical trials.
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.